Search research articles
Contact Us
Filters
Showing results (71-80 of 111) with videos related to
Page
of 12
Sort By:
Expert Opinion on Biological Therapy
|
January 19, 2022
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
Marco Galluzzo, Marina Talamonti, Laura Atzori, et al.
Cell Cycle (Georgetown, Tex.)
|
January 7, 2020
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo
Elena Campione, Caterina Lanna, Laura Diluvio, et al.
Clinical and Experimental Dermatology
|
June 27, 2025
Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region
Giacomo Caldarola, Eleonora De Luca, Simone Amato, et al.
International Journal of Dermatology
|
March 30, 2026
Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
April 26, 2024
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab
Filomena Russo, Vittoria Cioppa, Laura Lazzeri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 3, 2025
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
Niccolò Gori, Pietro Quaglino, Andrea Chiricozzi, et al.
Allergy
|
November 4, 2024
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis?
Enrico Scala, Stefania Madonna, Damiano Abeni, et al.
The Journal of Dermatological Treatment
|
June 9, 2025
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, et al.
Psoriasis (Auckland, N.Z.)
|
August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years
Luca Mastorino, Paolo Dapavo, Martina Burlando, et al.
Dermatology (Basel, Switzerland)
|
April 23, 2025
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas
Niccolò Gori, Marco Galluzzo, Andrea Chiricozzi, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 111) with videos related to
Sort By:
Page
of 12
Expert Opinion on Biological Therapy
|
January 19, 2022
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
Marco Galluzzo, Marina Talamonti, Laura Atzori, et al.
Cell Cycle (Georgetown, Tex.)
|
January 7, 2020
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo
Elena Campione, Caterina Lanna, Laura Diluvio, et al.
Clinical and Experimental Dermatology
|
June 27, 2025
Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region
Giacomo Caldarola, Eleonora De Luca, Simone Amato, et al.
International Journal of Dermatology
|
March 30, 2026
Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
April 26, 2024
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab
Filomena Russo, Vittoria Cioppa, Laura Lazzeri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 3, 2025
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
Niccolò Gori, Pietro Quaglino, Andrea Chiricozzi, et al.
Allergy
|
November 4, 2024
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis?
Enrico Scala, Stefania Madonna, Damiano Abeni, et al.
The Journal of Dermatological Treatment
|
June 9, 2025
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, et al.
Psoriasis (Auckland, N.Z.)
|
August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years
Luca Mastorino, Paolo Dapavo, Martina Burlando, et al.
Dermatology (Basel, Switzerland)
|
April 23, 2025
Evaluation of Upadacitinib Efficacy in the Treatment of Atopic Dermatitis of Sensitive Areas
Niccolò Gori, Marco Galluzzo, Andrea Chiricozzi, et al.
Page
of 12